117 related articles for article (PubMed ID: 37944330)
21. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
22. FIGO Grade 3 Endometrioid Adenocarcinomas With Diffusely Aberrant β-Catenin Expression: An Aggressive Subset Resembling Cutaneous Pilomatrix Carcinomas.
Weisman P; Park KJ; Xu J
Int J Gynecol Pathol; 2022 Mar; 41(2):126-131. PubMed ID: 33811207
[TBL] [Abstract][Full Text] [Related]
23. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association.
Kim G; Kurnit KC; Djordjevic B; Singh C; Munsell MF; Wang WL; Lazar AJ; Zhang W; Broaddus R
Mod Pathol; 2018 Oct; 31(10):1553-1559. PubMed ID: 29795437
[TBL] [Abstract][Full Text] [Related]
24. Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer.
Devis L; Moiola CP; Masia N; Martinez-Garcia E; Santacana M; Stirbat TV; Brochard-Wyart F; García Á; Alameda F; Cabrera S; Palacios J; Moreno-Bueno G; Abal M; Thomas W; Dufour S; Matias-Guiu X; Santamaria A; Reventos J; Gil-Moreno A; Colas E
J Pathol; 2017 Mar; 241(4):475-487. PubMed ID: 27873306
[TBL] [Abstract][Full Text] [Related]
25. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia.
Moreno-Bueno G; Hardisson D; Sarrió D; Sánchez C; Cassia R; Prat J; Herman JG; Esteller M; Matías-Guiu X; Palacios J
J Pathol; 2003 Apr; 199(4):471-8. PubMed ID: 12635138
[TBL] [Abstract][Full Text] [Related]
26. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma.
Yano M; Ito K; Yabuno A; Ogane N; Katoh T; Miyazawa M; Miyazawa M; Hasegawa K; Narahara H; Yasuda M
Mod Pathol; 2019 Jul; 32(7):1023-1031. PubMed ID: 30742011
[TBL] [Abstract][Full Text] [Related]
27. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
[TBL] [Abstract][Full Text] [Related]
28. Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer.
Long KC; Zhou Q; Hensley ML; Alektiar KM; Gomez J; Gardner GJ; Chi DS; Barakat RR; Abu-Rustum NR
Gynecol Oncol; 2012 Apr; 125(1):99-102. PubMed ID: 22112609
[TBL] [Abstract][Full Text] [Related]
29. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
30. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
31. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen.
Turbiner J; Moreno-Bueno G; Dahiya S; Sánchez-Estevez C; Hardisson D; Prat J; Oliva E; Palacios J
Mod Pathol; 2008 Aug; 21(8):925-36. PubMed ID: 18500270
[TBL] [Abstract][Full Text] [Related]
33. Ultrastaging of 'negative' pelvic lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer who developed non-vaginal recurrences.
Gill SE; Garzon S; Multinu F; Hokenstad AN; Casarin J; Cappuccio S; McGree ME; Weaver AL; Cliby WA; Keeney GL; Mariani A
Int J Gynecol Cancer; 2021 Dec; 31(12):1541-1548. PubMed ID: 34706876
[TBL] [Abstract][Full Text] [Related]
34. Comparable outcome between endometrioid and non-endometrioid tumors in patients with early-stage high-grade endometrial cancer.
Reynaers EA; Ezendam NP; Pijnenborg JM
J Surg Oncol; 2015 May; 111(6):790-4. PubMed ID: 25900897
[TBL] [Abstract][Full Text] [Related]
35. Defining prognostic variables in recurrent endometrioid endometrial cancer: a 15-year single-institution review.
Esselen KM; Boruta DM; del Carmen M; Schorge JO; Goodman A; Growdon WB
Int J Gynecol Cancer; 2011 Aug; 21(6):1078-83. PubMed ID: 21633304
[TBL] [Abstract][Full Text] [Related]
36. Factors predicting recurrence in patients with stage IA endometrioid endometrial cancer: what is the importance of LVSI?
Ureyen I; Karalok A; Turkmen O; Kimyon G; Akdas YR; Akyol A; Tasci T; Turan T
Arch Gynecol Obstet; 2020 Mar; 301(3):737-744. PubMed ID: 31883046
[TBL] [Abstract][Full Text] [Related]
37. Recurrence patterns and prognostic factors in lymphovascular space invasion-positive endometrioid endometrial cancer surgically confined to the uterus.
Sahin H; Meydanli MM; Sari ME; Kocaman E; Cuylan ZF; Yalcin I; Coban G; Özen Ö; Sirvan L; Güngör T; Ayhan A
Taiwan J Obstet Gynecol; 2019 Jan; 58(1):82-89. PubMed ID: 30638487
[TBL] [Abstract][Full Text] [Related]
38. Squamous differentiation portends poor prognosis in low and intermediate-risk endometrioid endometrial cancer.
Andrade DAP; da Silva VD; Matsushita GM; de Lima MA; Vieira MA; Andrade CEMC; Schmidt RL; Reis RM; Dos Reis R
PLoS One; 2019; 14(10):e0220086. PubMed ID: 31600211
[TBL] [Abstract][Full Text] [Related]
39. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
40. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
